Rapid, precise and non-invasive in vivo assessment of gene therapy and antitumor efficacy in deep tissue tumor models is feasible through the use of luciferase reporters and bioluminescence imaging (BLI). BLI is well-suited for quantifying tumor growth and treatment pharmacodynamics in orthotopic, hematologic and metastasis models of cancer.
Since luciferase reporters can be relatively easily and effectively incorporated into these biologic platforms, BLI has become the preferred platform for screening prior to moving into early clinical studies. Furthermore, luciferase can be used to test gene reporter platforms using translational gene reporters, such as HSV-TK.
In this webinar, Dr. McConville will provide an overview of state-of-the art-applications that utilize luciferase reporters and bioluminescent imaging, including gene delivery and oncolytic virus examples. Dr. Timberlake will showcase bioluminescence imaging based screening approaches to interrogate CAR-T cell efficacy, tracking and activation.
After this webinar you will understand:
Dr. McConville has 20 years experience in multi-modality drug discovery and translational imaging, working across all major disease areas, with a particular focus in oncology. After receiving his Ph.D. in Medical Physics (Queensland University of Technology, Australia) and conducting postdoctoral work at the NIH, Dr. McConville cofounded the first translational imaging CRO. In 2014, Dr. McConville launched a new state of the art in vivo imaging center in La Jolla, CA, and currently oversees continuing commercial and academic work there in his roles at the Konica Minolta company, Invicro and UCSD.
Dr. Timberlake has 10 years of experience developing gene and cell therapies for cancer and rare diseases. She received a doctorate in Medical and Molecular Pharmacology from UCLA and subsequently moved to San Diego to complete a Postdoctoral Fellowship at the Scripps Research Institute. Originally trained in viral gene delivery, Nina joined the Gene Therapy team at Poseida Therapeutics 3 years ago to help develop the next generation of cell therapies using Poseida’s cutting-edge non-viral gene delivery technology. Her projects include preclinical development of novel hematopoietic stem cell and CAR-T cell therapeutics.